New agents for the treatment of lymphoma

CD20 antibodies: doing the time warp

(2011) M. S. Cragg   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

(2011) V. Blanc et al.   CLINICAL CANCER RESEARCH

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma

(2011) Daruka Mahadevan et al.   JOURNAL OF CLINICAL ONCOLOGY

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

New drugs for aggressive B-cell and T-cell lymphomas

(2010) Niels Murawski et al.   LANCET ONCOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Beyond chemotherapy: new agents for targeted treatment of lymphoma

(2010) Anas Younes   Nature Reviews Clinical Oncology

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

(2008) Jessica K Altman et al.   CURRENT OPINION IN HEMATOLOGY

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE